

ORIOLA CORPORATION'S INTERIM REPORT 1 January–30 September 2023

Released on 31 October 2023 at 8.30 a.m.



Oriola Corporation's Interim Report 1 January–30 September 2023

Solid sales growth in Distribution business, strong financial position

July–September 2023 highlights

- Invoicing was EUR 861.7 (870.6) million and slightly below the previous year's level. On a constant currency basis, invoicing increased by 5.7% and was EUR 920.6 million.
- Net sales decreased by 5.7% to EUR 352.6 (373.9) million. On a constant currency basis, net sales increased by 0.7% and were EUR 376.5 million.
- Adjusted EBIT was EUR 4.4 (6.6) million. On a constant currency basis, the adjusted EBIT was EUR 4.7 million.
- EBIT was EUR -17.1 (6.3) million and included adjusting items of EUR -21.6 (-0.3) million mainly related to an impairment loss on goodwill in Dose dispensing cash generating unit. On a constant currency basis, EBIT was EUR -16.9 million.
- Profit for the period totalled EUR -20.2 (5.3) million and earnings per share were EUR -0.11 (0.03).

Excluding Swedish dose business:

- After the reporting period, Oriola announced the sale of Svensk dos AB to Apotekstjänst Sverige AB and issued a new outlook.
- Net sales were EUR 350.6 (354.0) million.
- Adjusted EBIT was EUR 5.2 (4.8) million.

January–September 2023 highlights

- Invoicing decreased by 1.4% to EUR 2,624.4 (2,661.2) million. On a constant currency basis, invoicing increased by 4.3% and was EUR 2,775.6 million.
- Net sales decreased by 4.4% to EUR 1,090.9 (1,141.3) million. On a constant currency basis, net sales increased by 1.1% and were EUR 1,153.4 million.
- Adjusted EBIT was EUR 11.3 (16.8) million. On a constant currency basis, the adjusted EBIT was EUR 11.9 million.
- EBIT was EUR -10.5 (16.6) million and included adjusting items of EUR -21.8 (-0.2) million mainly related to an impairment loss on goodwill in Dose dispensing cash generating unit. On a constant currency basis, EBIT was EUR -9.9 million.
- Profit for the period totalled EUR -17.9 (12.9) million and earnings per share were EUR -0.10 (0.07).

Excluding Swedish dose business:

- Net sales were EUR 1,075.3 (1,081.1) million.
- Adjusted EBIT was EUR 13.3 (10.2) million.

Key figures EUR million	2023 7-9	2022 7-9	Change %	2023 1-9	2022 1-9	Change %	2022 1-12
Continuing operations							
Invoicing	861.7	870.6	-1.0	2,624.4	2,661.2	-1.4	3,568.0
Net sales	352.6	373.9	-5.7	1,090.9	1,141.3	-4.4	1,515.5
Adjusted EBIT ^{1, 2}	4.4	6.6	-33.2	11.3	16.8	-32.7	19.7
EBIT	-17.1	6.3	-371.0	-10.5	16.6	-163.0	9.5
Adjusted EBIT %	1.3	1.8		1.0	1.5		1.3
EBIT %	-4.9	1.7		-1.0	1.5		0.6
Profit for the period	-20.2	5.3	-482.2	-17.9	12.9	-239.4	4.8
Earnings per share, EUR, continuing operations	-0.11	0.03		-0.10	0.07		0.03
Earnings per share, EUR, discontinued operations		0.05			0.12		-0.04
Net cash flow from operating activities ³	10.1	-25.8		-13.3	41.8		77.9
Gearing, % ³				-0.9	15.5		-10.5
Equity ratio, % ³				19.3	21.8		23.8
Return on capital employed (ROCE), % ³				-4.2	4.9		2.4

¹ Year 2022 Adjusted EBIT and EBIT have been restated and exclude the share of result in joint venture.

² Adjusting items are specified in note Adjusting items.

³ Comparative figures include continuing and discontinued operations.

In order to reflect the underlying business performance and to enhance comparability between financial periods, Oriola discloses certain performance measures of historical performance, financial position and cash flows, as permitted in the "Alternative performance measures" guidance issued by the European Securities and Markets Authority (ESMA). These measures should not be considered as a substitute for measures of performance in accordance with the IFRS. The calculation methods of these measures are provided in note Alternative performance measures in the notes to this Interim Report.

Outlook for 2023

Oriola issued a new outlook on 13 October 2023:

Oriola expects the adjusted EBIT, excluding the dose dispensing business in Sweden, for the year 2023 to be on the same level as adjusted EBIT for 2022 (EUR 19.7 million).

Oriola's adjusted EBIT, excluding the dose dispensing business in Sweden, for the year 2022 was EUR 11.9 million. The adjusted EBIT for the dose dispensing business in Sweden was EUR 7.8 million in 2022 and EUR -1.2 million in Q1-Q2 2023.

The recent overall inflationary environment and related cost pressures may have an impact on Oriola's profitability.

Oriola's adjusted EBIT in 2022 was EUR 19.7 million, excluding the contribution from the joint venture company Swedish Pharmacy Holding AB.

CEO Katarina Gabrielson:

The stable sales development continued in the third quarter. Oriola's net sales on a constant currency basis were EUR 376.5 million, which is at last year's level. We saw good development in our core business, the Distribution of pharmaceuticals, especially in Sweden. This has offset the negative impact of lower volumes in the Swedish dose dispensing business. Our share of the pharmaceutical distribution market remained stable both in Sweden and Finland. During the third quarter the overall development in the pharmaceutical distribution market was a bit softer than during the first half of the year, although we believe that the solid underlying long-term market drivers remain unchanged.

Adjusted EBIT declined from the previous year to EUR 4.4 (6.6) million. Profitability in the third quarter was mainly burdened by lower volumes in the Swedish dose dispensing business and as the Swedish krona has further weakened it has had some impact on the EBIT-line as well. Adjusted EBIT on a constant currency basis was EUR 4.7 million. Adjusted EBIT excluding Swedish dose business was EUR 5.2 (4.8) million. Operating expenses were below last year's level mainly following the restructuring of the Swedish dose dispensing business. Oriola's financial position has remained strong with a positive cash flow from operating activities in the third quarter and net working capital at a normalised level. At the end of the reporting period, net debt was close to zero.

In the third quarter, we have continued to focus on developing our commercial and supply chain excellence while ensuring profitability, efficiency and a collaborative culture. We have continued to strengthen our commercial capabilities with training and our focus is strongly on enhancing our understanding of how we can increasingly create relevance and value to our customers. The tighter collaboration between the sales teams and supply-demand planning improves our efficiency in deliveries.

The decline of adjusted EBIT in the joint venture company Kronans Apotek related to lower revenues compared to Q2 mainly affected by customer flows. A focus within Kronans Apotek remains on operations and integration activities, and synergies are proceeding according to plan.

In October, after the reporting period, we announced the sale of Svensk dos AB to Apotekstjänst Sverige AB. Consequently, we will exit the dose dispensing business in Sweden. Svensk dos has lost market share during the past 12 months and in our ongoing strategy review we have not identified a recovery in the foreseeable future of the business due to the prevailing Swedish tender market conditions. While this transaction gives continuity to Svensk dos, it also supports our decision to strengthen focus on our core distribution business. The transaction is subject to approval by the Swedish Competition Authority, and we expect it to be completed no later than in the first quarter of 2024. Going forward, we aim to deepen our pharmacy health products supply cooperation with Apotekstjänst.

In connection with the announcement about Svensk dos AB, we gave a new outlook for 2023. We expect the adjusted EBIT, excluding the dose dispensing business in Sweden, for the year 2023 to be on the same level as adjusted EBIT for 2022 (EUR 19.7 million). The recent overall inflationary environment and related cost pressures may have an impact on Oriola's profitability.

We continue to focus on the long-term transformation of Oriola. Our people have shown great dedication and motivation during the whole year, and this is something I am very proud of.

Oriola Corporation's Interim Report 1 January–30 September 2023

Operating environment

High cost inflation and rising interest rates have impacted consumer confidence and weakened consumers' expectations of their own economy. In the third quarter, volumes in the pharmaceutical distribution market were somewhat softer than in the first half of the year, while the market value continued a steady growth. The solid underlying long-term market drivers such as ageing population, wellbeing and health remain unchanged.

The availability of raw materials for pharmaceuticals has remained tight, and this has affected the availability of some medicines in Sweden and Finland. Energy and fuel prices have stabilised.

Market environment

In Sweden, the value of the pharmaceutical distribution market at wholesale prices, measured in Swedish krona, grew by 9.5% (7.8%) in January-September and by 8.7% (6.6%) in the third quarter (source: IQVIA). In Finland, the market value grew by 3.2% (4.6%) in January-September and by 1.8% (4.3%) in the third quarter (source: Pharmaca Health Intelligence). According to Oriola's estimate, the company's share of the pharmaceutical distribution market in Sweden was approximately 44% (45%) in January-September as well as in the third quarter. Oriola estimates that, the company's share of the pharmaceutical distribution market in Finland was approximately 44% (44%) in January-September and 45% (44%) in the third quarter.

In the dose dispensing business, Oriola offers pharmaceuticals and dose dispensing for private and public healthcare sector operators. The total market size for dose dispensing is approximately 270,000 patients (260,000) in Sweden and 110,000 patients (100,000) in Finland. Oriola serves approximately 11,000 (75,000) patients in Sweden and 30,000 (30,000) patients in Finland. The decline in the number of patients in Sweden was related to the loss of public tenders, as communicated earlier.

Group financial performance July-September 2023

Invoicing and net sales

Invoicing was EUR 861.7 (870.6) million and slightly below the previous year's level. The weak Swedish krona had a negative impact on reported invoicing and net sales figures. On a constant currency basis, invoicing increased by 5.7%. Net sales decreased by 5.7% to EUR 352.6 (373.9) million. On a constant currency basis, net sales increased by 0.7%. Sales were supported by the solid development in the Distribution of pharmaceuticals especially in Sweden. This has offset the negative impact of lower volumes in the Swedish dose dispensing business.

Profitability

Adjusted EBIT decreased to EUR 4.4 (6.6) million due to the low volumes in the Swedish Dose dispensing business. This decline was related to the loss of public tenders and consequently fewer patients. The further weakening of the Swedish krona has had some impact on the EBIT-line as well. Adjusted EBIT on a constant currency basis was EUR 4.7 million. Operating expenses were below last year's level, largely driven by cost reductions in the Swedish Dose dispensing business. Adjusting items totalled EUR -21.6 (-0.3) million mainly related to an impairment loss on goodwill in Dose dispensing cash generating unit. EBIT was EUR -17.1 (6.3) million.

In the third quarter of 2023, Oriola recognised a loss of EUR 0.6 million from Swedish Pharmacy Holding AB in the consolidated statement of comprehensive income.

Net financial expenses increased to EUR 1.9 (-0.4) million mainly due to higher interest rates. Profit for the period was EUR -20.2 (5.3) million. Earnings per share were EUR -0.11 (0.03).

Group financial performance January-September 2023

Invoicing and net sales

Invoicing decreased by 1.4% to EUR 2,624.4 (2,661.2) million. The weak Swedish krona had a negative impact on reported invoicing and net sales figures. On a constant currency basis, invoicing increased by 4.3%. Net sales decreased by 4.4% to EUR 1,090.9 (1,141.3) million. On a constant currency basis, net sales increased by 1.1%. Sales were supported by the solid development in the Distribution of pharmaceuticals.

Profitability

Adjusted EBIT decreased to EUR 11.3 (16.8) million due to lower volumes in Swedish Dose dispensing. This decline was related to the loss of public tenders and consequently fewer patients. As a result of cost restructuring in the Swedish dose dispensing and strict cost control, operating expenses were below last year's level despite the inflationary environment. Adjusting items totalled EUR -21.8 (-0.2) million mainly related to an impairment loss on goodwill in Dose dispensing cash generating unit. Adjusted EBIT on a constant currency basis was EUR 11.9 million. EBIT was EUR -10.5 (16.6) million.

In January-September 2023, Oriola recognised a loss of EUR 0.9 million from Swedish Pharmacy Holding AB in the consolidated statement of comprehensive income.

Net financial expenses were EUR 5.3 (-0.1) million mainly due to higher interest rates. Profit for the period was EUR -17.9 (12.9) million. Earnings per share were EUR -0.10 (0.07).

Joint venture Swedish Pharmacy Holding AB (Kronans Apotek)

Starting from the first quarter of 2023, Oriola reports its share of the net result in the Swedish Pharmacy Holding AB under the EBIT line in the consolidated statement of comprehensive income. Comparative information has been restated accordingly. In 2022 consolidated financial statements the share of the net result was reported above the EBIT line. The change clarifies the reporting and communication of Oriola's own operations performance and profitability.

Key figures	2023	2022	Change	2023	2022	Change	2022
EUR million	7-9	7-9	%	1-9	1-9	%	1-12
Net sales	275.0	287.6	-4.4	843.4	881.5	-4.3	1,158.2
EBITA	1.8			7.2			
EBITA %	0.7			0.9			
Adjusted EBIT	0.8			3.1			
Adjusted EBIT %	0.3			0.4			
Net interest-bearing debt				62.3			

In the third quarter of 2023, Swedish Pharmacy Holding AB reported net sales of EUR 275.0 (287.6) million. EBITA (Earnings before interest, taxes and amortization) was EUR 1.8 million. Adjusted EBIT was EUR 0.8 million, synergies during the reporting period totalled to EUR 3.5 million and one-off costs related to the integration of the two companies was EUR 1.2 million. At the end of September 2023, net interest-bearing debt was EUR 62.3 million.

In January-September 2023, net sales were EUR 843.4 (881.5) million. EBITA was EUR 7.2 million. Adjusted EBIT was EUR 3.1 million, synergies during the first three quarters totalled to EUR 8.2 million and one-off costs related to the integration of the two companies was EUR 2.7 million.

The adjusted EBIT related to lower revenues compared to Q2 mainly affected by customer flows. A focus within Kronans Apotek remains on operations and integration activities.

Oriola is committed to long-term ownership in Swedish Pharmacy Holding AB, and to support its value creation. The estimated annual synergies of EUR 25 million on EBITDA level are expected to be realised by the end of 2025. Oriola published illustrative financial information for Swedish Pharmacy Holding AB in connection with the publication of the transaction (9 February 2022). The illustrative net sales of Swedish Pharmacy Holding AB in 2022 were EUR 1,158 million.

Sustainability

Oriola takes pride in enhancing the availability and safe use of medicines and healthcare products. By combining the expertise and resources of Oriola and its customers, the company also contributes to the more sustainable development of society. Around half of the pharmaceuticals used in Finland and Sweden pass through Oriola.

Oriola's sustainability programme is integrated in the company's strategy and structured under three focus areas: Planet, Society and People. For each of these, ambitious long-term sustainability goals have been set.

More information about Oriola's sustainability work can be found on the company website:

<https://www.oriola.com/sustainability/>

Preparedness to comply with the EU Corporate Sustainability Reporting Directive

Oriola is preparing to comply with the EU Corporate Sustainability Reporting Directive (CSRD), and to report according to the directive for the financial year 2024. As part of the readiness project, a gap analysis to identify key development areas was completed in January 2023, and a double-materiality assessment survey was completed in March 2023. Based on the survey results, Oriola is renewing its sustainability agenda including strategic targets and KPIs. During the third quarter, Oriola has initiated a Human Rights Due Diligence project to identify and assess the salient human rights impacts and risks across Oriola's value chain. Oriola also has ongoing projects to develop ESG data and data management.

Balance sheet, cash flow and financing

Oriola's total assets at the end of September 2023 were EUR 922.4 (1,081.9) million. Equity attributable to the equity holders was EUR 174.1 (231.4) million. In line with the decision of the Annual General Meeting the company paid dividends of EUR 10.9 million in April. In the third quarter a further decrease of EUR 1.1 million was recognised in the fair value of shareholdings in Doktor.se due to the realised transactions at lower price. In total, a decrease of EUR 20.6 million has been recorded in the fair value during the reporting period. Oriola's ownership of shares in Doktor.se has not changed during the reporting period.

Cash and cash equivalents totalled EUR 130.3 (123.4) million. Net cash flow from operating activities in January–September 2023 was EUR -13.3 (41.8) million, of which changes in working capital accounted for EUR -26.8 (-5.0) million. Increase in inventories and in trade receivables have impacted working capital negatively. Strong fluctuation in working capital is typical for Oriola's industry. Net cash flow from investing activities was EUR -2.4 (-3.5) million. Net cash flow from financing activities was EUR -14.6 (-7.5) million.

At the end of September 2023, interest-bearing debt was EUR 128.7 (159.2) million. Non-current interest-bearing liabilities amounted to EUR 36.3 (71.0) million and current interest-bearing liabilities amounted to EUR 92.4 (88.2) million. Non-current interest-bearing liabilities mainly consist of loans from financial institutions totalling EUR 31.0 (59.6) million and non-current lease liabilities totalling EUR 5.3 (11.4) million. Current interest-bearing liabilities mainly consist of commercial paper issues of EUR 44.6 (59.9) million, advance payments from Finnish pharmacies totalling EUR 18.0 (22.7) million, loans from financial institutions totalling EUR 27.1 (2.0) million and current lease liabilities totalling EUR 2.6 (3.6) million. Interest-bearing net debt was EUR -1.6 (35.8) million and gearing -0.9% (15.5%).

Non-recourse trade receivables sales programmes are in use in Sweden. At the end of September 2023, a total of EUR 92.8 (169.4) million in trade receivables had been sold. The average interest rate on the interest-bearing liabilities excluding lease liabilities was 3.51% (1.70%). Interest rate risk relating to the cash flow from selling of trade receivables has been partly hedged with interest rate swaps.

In June 2021, Oriola signed a new unsecured revolving credit facility agreement totalling EUR 140 million. In April 2023, the maturity of the agreement was extended by one year, and the revolving credit facility will mature in 2026. The margin of the revolving credit facility is linked to Oriola's financial covenants and the performance of sustainability targets. The committed long-term revolving credit facility of EUR 140.0 million and the credit limits totalling EUR 34.3 million were unused at the end of September 2023.

At the end of September 2023, Oriola's equity ratio was 19.3% (21.8%). Return on capital employed was -4.2% (4.9%) and return on equity was -11.8% (7.7%).

Investments and depreciation

Gross investments in January–September 2023 totalled EUR 2.0 (2.1) million and consisted mainly of investments in logistics and information systems.

Depreciation, amortisation and impairment amounted to EUR 32.4 (11.2) million. Oriola recognised an impairment loss of goodwill totalling EUR 21.4 million in the dose dispensing cash generating unit.

Personnel

At the end of September 2023, Oriola had 754 (859) employees, of which 411 (401) worked in Finland and 343 (458) in Sweden. The decrease in the number of personnel was due to organisational changes in the Swedish Dose business. The average number of personnel in January–September 2023 was 806 (940). The reported number of personnel consists of members of staff in active employment, calculated as full-time equivalents.

Corporate Governance

Composition of Oriola Corporation's Shareholders' Nomination Board

On 27 September 2023, the largest shareholders of Oriola Corporation appointed the following persons as members of the Nomination Board:

- Annika Ekman
- Peter Immonen
- Timo Maasilta
- Pekka Pajamo
- Jukka Ylppö

Pekka Pajamo was elected chairman of the Nomination Board.

Heikki Westerlund, Chairman of the Board of Directors of Oriola, serves as an expert member of the Nomination Board.

Oriola Corporation shares

Trading of shares	Jan–Sep 2023		Jan–Sep 2022	
	class A	class B	class A	class B
Trading volume, million	1.5	35.0	6.1	25.7
Trading value, EUR million	2.2	40.0	12.2	51.7
Highest price, EUR	1.93	1.82	2.30	2.31
Lowest price, EUR	1.05	0.89	1.76	1.72
Closing quotation, end of period, EUR	1.14	0.93	1.85	1.78

Oriola Corporation's market capitalisation on 30 September 2023 was EUR 180.3 (327.1) million.

In January–September 2023, the traded volume of Oriola Corporation shares, excluding treasury shares, corresponded to 20.2% (17.5%) of the total number of shares.

At the end of September 2023, the company had a total of 181,486,213 (181,486,213) shares, of which 53,748,313 (53,748,313) were class A shares and 127,737,900 (127,737,900) were class B shares. The company held a total of 87,426 (109,564) treasury shares, of which 63,650 (63,650) were class A shares and 23,776 (45,914) were class B shares. The treasury shares held by the company account for 0.05% (0.06%) of the company's shares and 0.11% (0.11%) of the votes.

Under Article 3 of the Articles of Association, a shareholder may demand conversion of class A shares into class B shares. During the period January–September 2023, no class A shares were converted into class B shares.

Risks and uncertainty factors

Oriola's risk management seeks to identify, measure and manage risks that may threaten Oriola's operations and the achievement of set goals.

Oriola operates in regulated pharmaceutical distribution and retail markets monitored by authorities in both its operating countries. The main trends impacting Oriola's business environment are ageing of the population, increased spending on health and wellbeing, growth in speciality pharmaceuticals, the digitalisation of the retail trade and services, as well as sustainability.

More information on Oriola's risks and risk management can be found on Oriola's website at www.oriola.com/investors/corporate-governance/risks/.

Near-term risks and uncertainty factors

Risks related to instability in financial markets, cost inflation, salary inflation and overheated labour markets, uncertain product availability due to material and supply chain constraints, and electricity shortages, remain. In addition, cyber-attacks against critical areas of society are expected to increase. These factors may have a significant impact on Oriola's operations, net sales and profitability.

Oriola is deemed as a critical entity under the directive (2022/2557) of the European Parliament on the resilience of critical entities. Recognition of full-service healthcare distributors as critical infrastructure reduces Oriola's risks. The directive entered into force on 16 January 2023 and will have to be implemented at national level.

In regular contingency planning, the company has focused especially on securing the health of its personnel, availability of workforce and safety in the distribution centres, as well as the growing need for pharmaceutical stocking. In addition, Oriola engages in active dialogue with both customers and authorities about the quickly changing requirements and how to manage them. Oriola also aims to actively mitigate cost pressures.

Oriola's strategic development projects involve operational risks which may have an effect on the company's profitability if realised. Oriola has IT system projects underway. The company has defined separate risk management plans for all major IT projects and aims to ensure seamless implementation of the systems through careful planning.

Oriola's distribution capabilities relies on automation and information systems. If the systems experience long or short-term malfunctions, Oriola's delivery accuracy might be affected.

From time to time, Oriola is involved in legal actions, claims and other proceedings. It is Oriola's policy to provide for amounts related to the proceedings if liability is probable, and such amounts can be estimated with reasonable accuracy. Taking into account all available information to date, legal actions, claims and other proceedings are not expected to have a material impact on the financial position of the Group.

Outlook for 2023

Oriola issued a new outlook on 13 October 2023:

Oriola expects the adjusted EBIT, excluding the dose dispensing business in Sweden, for the year 2023 to be on the same level as adjusted EBIT for 2022 (EUR 19.7 million).

Oriola's adjusted EBIT, excluding the dose dispensing business in Sweden, for the year 2022 was EUR 11.9 million. The adjusted EBIT for the dose dispensing business in Sweden was EUR 7.8 million in 2022 and EUR -1.2 million in Q1-Q2 2023.

The recent overall inflationary environment and related cost pressures may have an impact on Oriola's profitability.

Oriola's adjusted EBIT in 2022 was EUR 19.7 million, excluding the contribution from the joint venture company Swedish Pharmacy Holding AB.

Events after the period

Oriola to sell Svensk dos AB to Apotekstjänst Sverige AB

Oriola announced on 13 October 2023 that it had signed an agreement to sell all shares in Svensk dos AB to Apotekstjänst Sverige AB, and is thereby exiting the dose dispensing business in Sweden.

The agreed sales price in cash is SEK 110 million (approximately EUR 9.5 million). The transaction is subject to the approval of the Swedish Competition Authority (Konkurrensverket) and is expected to be completed no later than in the first quarter of 2024.

Svensk dos will be classified as held-for-sale in Oriola's consolidated financial statements starting from October 2023. In connection with the announcement, Oriola issued a new outlook for 2023. More information in the [stock exchange release](#) on Oriola's website.

Next financial report

Oriola will publish its Financial Statements Release for January-December 2023 on 16 February 2024.

Espoo, 30 October 2023

Oriola Corporation
Board of Directors

Consolidated statement of comprehensive income (IFRS)

EUR million	2023 7-9	2022 7-9	2023 1-9	2022 1-9	2022 ¹ 1-12
Continuing operations					
Net sales	352.6	373.9	1,090.9	1,141.3	1,515.5
Other operating income	1.0	2.7	2.2	4.7	5.8
Materials and supplies	-315.5	-327.5	-971.4	-1,000.0	-1,329.6
Employee benefit expenses	-11.5	-13.1	-40.4	-46.7	-61.1
Other operating expenses	-18.6	-25.9	-59.3	-71.5	-95.9
Depreciation, amortisation and impairments	-25.2	-3.8	-32.4	-11.2	-25.2
EBIT	-17.1	6.3	-10.5	16.6	9.5
Financial income and expenses	-1.9	0.4	-5.3	0.1	-0.7
Share of results in joint venture	-0.6	-	-0.9	-	-2.0
Profit before taxes	-19.7	6.7	-16.7	16.7	6.9
Income taxes	-0.5	-1.4	-1.2	-3.8	-2.1
Profit for the period from continuing operations	-20.2	5.3	-17.9	12.9	4.8
Profit for the period from discontinued operations	-	9.3	-	22.6	-7.2
Profit for the period	-20.2	14.6	-17.9	35.5	-2.4
Other comprehensive income					
Items which may be reclassified subsequently to profit or loss:					
Translation differences recognised in comprehensive income during the reporting period	1.5	-4.2	-2.2	-16.2	40.8
Translation differences reclassified to profit and loss during the reporting period	-	-	-	-	-29.0
Cash flow hedge	-0.1	0.3	-0.3	3.0	2.8
Income tax relating to other comprehensive income	0.0	-0.1	0.1	-0.6	-0.6
	1.4	-4.0	-2.4	-13.8	13.9
Items which will not be reclassified to profit or loss:					
Financial assets recognised at fair value through other comprehensive income	-1.1	-	-20.6	-	-
Actuarial gains/losses on defined benefit plans	-	-	-	-	5.2
Income tax relating to other comprehensive income	-	-	-	-	-1.1
	-1.1	-	-20.6	-	4.2
Total comprehensive income for the period	-20.0	10.6	-40.9	21.7	15.7
Profit attributable to					
Parent company shareholders	-20.2	14.6	-17.9	35.5	-2.4
Total comprehensive income attributable to					
Parent company shareholders	-20.0	10.6	-40.9	21.7	15.7

¹ Comparative information has been restated. Share of result in joint venture is reported under EBIT.

EUR million	2023 7-9	2022 7-9	2023 1-9	2022 1-9	2022 1-12
Earnings per share attributable to parent company shareholders:					
EUR					
Basic					
Continuing operations	-0.11	0.03	-0.10	0.07	0.03
Discontinued operations	-	0.05	-	0.12	-0.04
Group total	-0.11	0.08	-0.10	0.20	-0.01
Diluted					
Continuing operations	-0.11	0.03	-0.10	0.07	0.03
Discontinued operations	-	0.05	-	0.12	-0.04
Group total	-0.11	0.08	-0.10	0.20	-0.01

Consolidated statement of financial position (IFRS)

EUR million	30 Sep 2023	30 Sep 2022	31 Dec 2022
Non-current assets			
Property, plant and equipment	46.7	63.7	57.7
Goodwill	39.6	61.1	61.1
Other intangible assets	18.0	28.2	20.6
Investments in joint ventures	239.6	-	240.4
Other non-current assets	17.2	38.6	38.3
Deferred tax assets	1.5	2.8	1.2
Non-current assets total	362.7	194.4	419.1
Current assets			
Inventories	173.6	154.8	148.5
Trade receivables	249.9	182.9	226.8
Income tax receivables	2.4	0.1	1.1
Other receivables	3.6	5.9	4.7
Cash and cash equivalents	130.3	123.4	160.6
	559.7	467.1	541.8
Assets held for sale	-	420.4	-
Current assets total	559.7	887.5	541.8
Assets total	922.4	1,081.9	960.9

EUR million	30 Sep 2023	30 Sep 2022	31 Dec 2022
Equity			
Share capital	36.2	36.2	36.2
Fair value reserve	7.9	28.8	28.7
Contingency fund	19.4	19.4	19.4
Invested unrestricted equity reserve	74.8	74.8	74.8
Other reserves	0.1	0.1	0.1
Translation differences	-18.9	-44.6	-16.7
Retained earnings	54.8	116.7	83.2
Equity attributable to the parent company shareholders	174.1	231.4	225.6
Non-current liabilities			
Deferred tax liabilities	4.5	5.3	4.9
Pension obligations	10.8	17.9	11.8
Interest-bearing liabilities	36.3	71.0	69.9
Other non-current liabilities	0.3	0.5	0.7
Non-current liabilities total	52.0	94.7	87.3
Current liabilities			
Trade payables	577.1	535.9	557.3
Interest-bearing liabilities	92.4	88.2	67.0
Income tax payables	0.0	2.4	1.0
Other current liabilities	26.8	27.5	22.8
	696.3	654.0	648.0
Liabilities related to assets held for sale	-	101.8	-
Current liabilities total	696.3	755.8	648.0
Equity and liabilities total	922.4	1,081.9	960.9

Consolidated statement of changes in equity (IFRS)

EUR million	Share capital	Funds	Translation differences	Retained earnings	Equity total
Equity 1 Jan 2022	36.2	120.7	-28.5	88.3	216.8
Comprehensive income for the period					
Net profit for the period	-	-	-	35.5	35.5
Other comprehensive income:					
Cash flow hedge	-	3.0	-	-	3.0
Income tax relating to other comprehensive income	-	-0.6	-	-	-0.6
Translation difference	-	-	-16.2	-	-16.2
Comprehensive income for the period total	-	2.4	-16.2	35.5	21.7
Transactions with owners					
Dividend distribution	-	-	-	-7.3	-7.3
Share-based incentive	-	-	-	0.3	0.3
Purchase of own shares	-	-	-	-0.1	-0.1
Transactions with owners total	-	-	-	-7.1	-7.1
Equity 30 September 2022	36.2	123.1	-44.6	116.7	231.4
Equity 1 Jan 2023	36.2	122.9	-16.7	83.2	225.6
Comprehensive income for the period					
Net profit for the period	-	-	-	-17.9	-17.9
Other comprehensive income:					
Financial assets recognized at fair value through other comprehensive income:					
Change in fair value	-	-20.6	-	-	-20.6
Financial assets recognized at fair value through comprehensive income total	-	-20.6	-	-	-20.6
Cash flow hedge comprehensive income	-	-0.3	-	-	-0.3
Translation difference	-	0.1	-	-	0.1
Translation difference	-	-	-2.2	-	-2.2
Comprehensive income for the period total	-	-20.8	-2.2	-17.9	-40.9
Transactions with owners					
Dividend distribution	-	-	-	-10.9	-10.9
Share-based incentive	-	-	-	0.5	0.5
Purchase of own shares	-	-	-	-0.1	-0.1
Transactions with owners total	-	-	-	-10.5	-10.5
Equity 30 September 2023	36.2	102.1	-18.9	54.8	174.1

Consolidated statement of cash flows (IFRS)

EUR million	2023 1-9	2022 ¹ 1-9	2022 ¹ 1-12
Profit (loss) for the period	-17.9	35.5	-2.4
Adjustments for			
Depreciation, amortisation and impairments	32.4	14.4	28.1
Share of results in joint venture	0.9	-	2.0
Financial income and expenses	5.3	4.0	5.5
Loss on sale of discontinued operations	-	-	29.4
Income taxes	1.2	9.7	7.9
Other adjustments	0.5	-0.0	-0.9
Cash flow before change in working capital	22.4	63.6	69.6
Change in working capital	-26.8	-5.0	27.7
Cash flow from operating activities before financial items and taxes	-4.4	58.6	97.3
Financial income received and costs paid	-5.5	-13.1	-15.4
Taxes paid	-3.4	-3.7	-4.0
Net cash flow from operating activities	-13.3	41.8	77.9
Investments in property, plant and equipment and intangible assets	-2.5	-7.1	-8.5
Proceeds from sale of property, plant and equipment and intangible assets	0.0	0.4	0.4
Investments in joint ventures	-	-	24.3
Sales of subsidiaries and business operations, net of cash disposed	-	3.2	-13.1
Net cash flow from investing activities	-2.4	-3.5	3.0
Repayment of loans	-2.0	-2.0	-2.0
Change in other current financing	1.1	16.8	-4.2
Amortisations of lease liabilities	-2.7	-14.9	-15.7
Purchasing of own shares	-0.1	-0.1	-0.1
Dividends paid	-10.9	-7.3	-7.3
Net cash flow from financing activities	-14.6	-7.5	-29.3
Net change in cash and cash equivalents	-30.3	30.8	51.6
Cash and cash equivalents at the beginning of the period	160.6	109.1	109.1
Translation differences	-0.0	-0.6	-0.1
Net change in cash and cash equivalents	-30.3	30.8	51.6
Cash and cash equivalents at the end of the period	130.3	139.3	160.6

¹ Includes continuing and discontinued operations.

Notes to the Interim Report January–September 2023

Principal accounting policies

This Interim Report has been prepared in accordance with IFRS standards (IAS 34 Interim Financial Reporting) and should be read in conjunction with the Group's last consolidated financial statements as at and for the year ended 31 December 2022. The accounting policies and calculation methods applied in the release are the same as those in the 31 December 2022 financial statements, however with the addition of the standards and interpretations published by the International Accounting Standards Board (IASB) that are mandatory as of 1 January 2023. These standards did not have a significant impact on the Group in the current reporting period and they are not expected to have a material impact on the Group in the future reporting periods and on foreseeable future transactions. This Interim Report does not include all the information and notes presented in the financial statements. The figures in this Interim Report are unaudited.

Reporting the share of results in joint venture

Starting from the first quarter of 2023, Oriola reports its share of the net result in the Swedish Pharmacy Holding AB under the EBIT line in the consolidated statement of comprehensive income. Comparative information has been restated accordingly. In 2022 consolidated financial statements the share of the net result was reported above the EBIT line. The change clarifies the reporting and communication of Oriola's own operations performance and profitability.

Reporting segments

At the beginning of 2022, Oriola implemented a country-based organisation, where the Pharma and Retail business areas and the Operations function were transformed into a new organisational structure. Oriola reports these operations as one reportable segment.

Oriola offers advanced distribution, expert and advisory services for pharmaceutical companies and wide range of health and wellbeing products for pharmacies, veterinarians, other healthcare operators and retail operators in the Finnish and Swedish markets. Additionally, Oriola offers dose dispensing services for pharmacies and healthcare operators.

Earnings per share

EUR million	2023 7-9	2022 7-9	2023 1-9	2022 1-9	2022 ¹ 1-12
Profit attributable to equity owners of the parent					
Continuing operations	-20.2	5.3	-17.9	12.9	4.8
Discontinued operations	-	9.3	-	22.6	-7.2
Group total	-20.2	14.6	-17.9	35.5	-2.4
Average number of outstanding shares (1000 shares)					
Basic	181,399	181,377	181,387	181,369	181,371
Diluted	181,423	181,423	181,423	181,423	181,423
Earnings per share (EUR)					
Basic					
Continuing operations	-0.11	0.03	-0.10	0.07	0.03
Discontinued operations	-	0.05	-	0.12	-0.04
Group total	-0.11	0.08	-0.10	0.20	-0.01
Diluted					
Continuing operations	-0.11	0.03	-0.10	0.07	0.03
Discontinued operations	-	0.05	-	0.12	-0.04
Group total	-0.11	0.08	-0.10	0.20	-0.01

Discontinued operations

There were no discontinued operations in the Group during the reporting period. In 2022, discontinued operations included Consumer business area.

In February 2022, Oriola signed a framework merger agreement with the Euroapothecca group for combining the respective pharmacy businesses in Sweden: Oriola's Consumer business area comprising of Kronans Apotek and Euroapothecca's Apoteksgruppen into a new jointly owned company. Oriola's share is 50 per cent of the investment and the result. Oriola accounts its interest in the joint venture using the equity method.

The consolidated statement of comprehensive income has been represented to show the discontinued operations separately from continuing operations. The elimination of transactions between the continuing operations and the discontinued operations is attributed in a way that reflects the continuance of these transactions after the arrangement was completed.

The discontinued operations' result, assets and liabilities, and cash flows have been presented in the consolidated financial statements of 2022 and in the Interim Report in 2022.

Tangible and intangible assets

Changes in property, plant and equipment, EUR million	2023 1-9	2022 1-9	2022 1-12
Carrying amount at the beginning of the period	43.9	76.6	76.6
Increases	1.1	2.4	3.2
Decreases	-0.0	-0.1	-0.1
Disposals of operations	-	-	-20.9
Reclassifications between asset categories	0.0	0.4	0.4
Reclassifications to assets held for sale	-	-21.2	-
Depreciation, continuing operations	-4.7	-4.9	-6.6
Depreciation, discontinued operations	-	-0.5	-0.5
Impairments	-0.2	-	-3.7
Foreign exchange rate differences	-1.1	-3.6	-4.6
Carrying amount at the end of the period	39.0	49.1	43.9

Changes in right-of-use assets EUR million	2023 1-9	2022 1-9	2022 1-12
Carrying amount at the beginning of the period	13.8	79.4	79.4
Increases	1.5	4.5	5.5
Decreases	-4.7	-0.3	-0.6
Disposals of operations	-	-	-59.3
Reclassifications to assets held for sale	-	-60.2	-
Depreciation, continuing operations	-2.4	-2.8	-4.0
Depreciation, discontinued operations	-	-1.8	-1.7
Foreign exchange rate differences	-0.4	-4.2	-5.5
Carrying amount at the end of the period	7.6	14.6	13.8

Changes in goodwill, EUR million	2023 1-9	2022 1-9	2022 1-12
Carrying amount at the beginning of the period	61.1	273.5	273.5
Disposals of operations	-	-2.0	-196.6
Reclassifications to assets held for sale	-	-198.4	-
Impairments	-21.4	-	-
Foreign exchange rate differences	-0.1	-12.0	-15.8
Carrying amount at the end of the period	39.6	61.1	61.1

Changes in other intangible assets, EUR million	2023 1-9	2022 1-9	2022 1-12
Carrying amount at the beginning of the period	20.6	71.0	71.0
Increases	1.3	4.8	5.2
Decreases	-0.1	-0.8	-0.4
Disposals of operations	-	-	-39.8
Reclassifications	-0.0	-0.4	-0.4
Reclassifications to assets held for sale	-	-39.8	-
Amortization, continuing operations	-3.7	-3.5	-4.8
Amortization, discontinued operations	-	-0.8	-0.8
Impairments	-	-	-6.4
Foreign exchange rate differences	-0.1	-2.4	-3.1
Carrying amount at the end of the period	18.0	28.2	20.6

Derivatives

30 Sep 2023 EUR million	Positive fair value	Negative fair value	Nominal values of contracts
Derivatives recognised as cash flow hedges			
Interest rate swaps	3.0	-	52.0
Derivatives measured at fair value through profit or loss			
Interest rate swaps	0.5	-	10.4
Foreign currency forward and swap contracts	0.4	1.4	84.3

30 Sep 2022 EUR million	Positive fair value	Negative fair value	Nominal values of contracts
Derivatives recognised as cash flow hedges			
Interest rate swaps	3.5	-	55.0
Derivatives measured at fair value through profit or loss			
Foreign currency forward and swap contracts	0.2	0.1	131.4

Derivatives measured at fair value through profit or loss are mainly related to hedging of the Group's internal transactions. Fair values of the derivatives have been recognised in the balance sheet in gross amount as the derivatives contracts are related to credit events and cannot be netted in financial statements. The Group has not given nor received collateral to/from derivatives counterparties.

Fair value hierarchy

30 Sep 2023 EUR million	Level 1	Level 2	Level 3	Total
Assets				
Derivatives designated as hedges	-	3.0	-	3.0
Derivatives measured at fair value through profit or loss	-	0.8	-	0.8
Other investments measured at fair value through OCI	-	-	13.6	13.6
Trade receivables for sale	-	6.8	-	6.8
Liabilities				
Derivatives designated as hedges	-	-	-	-
Derivatives measured at fair value through profit or loss	-	1.4	-	1.4

30 Sep 2022 EUR million	Level 1	Level 2	Level 3	Total
Assets				
Derivatives designated as hedges	-	3.5	-	3.5
Derivatives measured at fair value through profit or loss	-	0.9	-	0.9
Other investments measured at fair value through OCI	-	-	34.2	34.2
Trade receivables for sale	-	12.5	-	12.5
Liabilities				
Derivatives measured at fair value through profit or loss	-	0.1	-	0.1

Level 1: Quoted prices (unadjusted) in active markets for identical assets or liabilities.

Level 2: Inputs other than quoted prices included within level 1 that are observable for the asset or liability, either directly (i.e., as prices) or indirectly (i.e., derived from prices).

Level 3: Inputs for the asset or liability that are not based on observable market data (i.e., unobservable inputs).

Reconciliation of financial assets recognised at fair value according to the level 3

	2023	2022	2022
Financial assets on level 3, EUR million	1-9	1-9	1-12
Carrying amount at the beginning of the period	34.2	34.2	34.2
Disposal of shares		-	-
Change in fair value	-20.6	-	-
Carrying amount at the end of the period	13.6	34.2	34.2

Financial assets recognised at fair value through other comprehensive income (level 3) include Oriola's holding in the Swedish online medical centre Doktor.se. The applied valuation method for the shares in Doktor.se is based on realised transactions. A decrease of EUR 20.6 million was recognised in the fair value of shareholdings in Doktor.se due to the realised transactions at lower price.

Commitments and Contingent Liabilities

EUR million	30 Sep 2023	30 Sep 2022	31 Dec 2022
Commitments for own liabilities			
Guarantees on behalf of own companies	6.4	6.7	6.5
Guarantees on behalf of other companies	0.1	-	0.3
Mortgages on company assets	1.8	1.9	1.9
Other guarantees and liabilities	3.8	5.8	5.8
Total	12.0	14.5	14.5
Committed future minimum lease liabilities	0.7	1.2	1.1

The most significant guarantees are bank guarantees against the Swedish wholesale company's trade payables. In addition, Oriola Corporation has granted parent company guarantees of EUR 0.2 (0.4) million against other subsidiaries' lease liabilities.

Committed future minimum lease liabilities consist of leasing commitments related to low-value assets and short-term leases, to which the Group elected to apply recognition exemptions permitted by IFRS 16.

Related parties

Related parties in the Oriola Group are deemed to comprise the members of the Board of Directors and the President and CEO of Oriola Corporation, the other members of the Oriola Management Team, the immediate family of the aforementioned persons and the companies controlled by the aforementioned persons, the Group's subsidiaries and joint ventures. The Group has transactions between the group companies in the ordinary course of business. The Group has no significant business transactions with other related parties.

Oriola reports 50 per cent of the result of the joint venture Swedish Pharmacy Holding AB below EBIT. The transactions with the joint venture are presented in the following table:

	2023	2022	2023	2022	2022
EUR million	7-9	7-9	1-9	1-9	1-12
Sales	120.9	-	372.7	-	130.9
Purchases of goods and services	0.1	-	0.3	-	0.1
Trade and other receivables	72.5	-	72.5	-	20.7
Trade and other payables	0.6	-	0.6	-	0.2
Commitments	0.1		0.1		0.3

Quarterly information

EUR million	2023 7-9	2023 4-6	2023 1-3	2022 10-12	2022 7-9	2022 4-6	2022 1-3
Invoicing	861.7	904.3	858.3	906.9	870.6	903.9	886.7
Net sales	352.6	383.6	354.7	374.2	373.9	394.6	372.7
Adjusted EBIT total	4.4	3.4	3.5	2.9	6.6	5.5	4.7
EBIT total	-17.1	3.2	3.5	-7.1	6.3	7.0	3.3
Number of personnel at the end of the period, FTE's total	754	797	830	833	859	899	1,039

Geographical information

1-9/2023 EUR million	Sweden	Finland	Other countries	Total
Net sales	614.7	391.5	84.8	1,090.9
Non-current assets ¹	66.7	290.9	-	357.6
Investments	0.2	1.8	-	2.0
Average number of personnel	394	412	-	806

1-9/2022 EUR million	Sweden	Finland	Other Countries	Total
Net sales	680.0	372.6	88.6	1,141.3
Non-current assets ¹	89.5	97.8	-	187.3
Investments	0.8	1.2	-	2.1
Average number of personnel	478	461	-	940

¹ Non-current assets exclude financial instruments and deferred tax assets.

Disaggregation of revenue

In the following table, the Group's revenue from continuing operations is disaggregated by the Group's major revenue streams.

EUR million	2023 1-9	2022 1-9	2022 1-12
Wholesale	981.4	965.7	1,287.9
Other ¹	109.6	175.6	227.6
Net sales total	1,090.9	1,141.3	1,515.5

¹ Other includes sales of logistics services, dose dispensing and other services. Sale of staffing services has been included in other until June 2022.

Alternative performance measures

Key figures	2023	2022	Change	2023	2022	Change	2022
EUR million	7-9	7-9	%	1-9	1-9	%	1-12
Invoicing	861.7	870.6	-1.0	2,624.4	2,661.2	-1.4	3,568.0
Net sales	352.6	373.9	-5.7	1,090.9	1,141.3	-4.4	1,515.5
Adjusted EBIT ¹	4.4	6.6	-33.2	11.3	16.8	-32.7	19.7
EBIT	-17.1	6.3	-371.0	-10.5	16.6	-163.0	9.5
Adjusted EBIT %	1.3	1.8		1.0	1.5		1.3
EBIT %	-4.9	1.7		-1.0	1.5		0.6
Profit for the period	-20.2	5.3	-482.2	-17.9	12.9	-239.4	4.8
Earnings per share, EUR	-0.11	0.03	-482.2	-0.10	0.07	-239.4	0.03
Net cash flow from operating activities ²	10.1	-25.8		-13.3	41.8		77.9
Gross capital expenditure				2.0	2.1		3.4
Net interest-bearing debt				-1.6	35.8		-23.7
Gearing, %				-0.9	15.5		-10.5
Equity per share, EUR				0.96	1.28		1.24
Equity ratio, %				19.3	21.8		23.8
Return on equity (ROE), %				-11.8	7.7		2.2
Return on capital employed (ROCE), %				-4.2	4.9		2.4
Average number of shares, 1000 pcs ³				181,387	181,369		181,371
Average number of personnel ⁴				806	940		914
Number of personnel at the end of the period ⁴				754	859		833

¹ Adjusting items are specified in note Adjusting items.

² Year 2022 includes discontinued operations.

³ Treasury shares held by the company not included.

⁴ Full time equivalents

Reconciliation of alternative performance measures to IFRS

Invoicing	2023	2022	2023	2022	2022
EUR million	7-9	7-9	1-9	1-9	1-12
Net sales	352.6	373.9	1,090.9	1,141.3	1,515.5
+ Acquisition cost of consignment stock	509.0	496.6	1,533.4	1,519.8	2,052.5
+ Cash discounts	0.0	0.0	0.0	0.0	0.1
+ Exchange rate differences on sales	0.2	0.0	0.0	0.0	0.0
Invoicing	861.7	870.6	2,624.4	2,661.2	3,568.0

Adjusted EBIT	2023	2022	2023	2022	2022
EUR million	7-9	7-9	1-9	1-9	1-12
EBIT	-17.1	6.3	-10.5	16.6	9.5
- Adjusting items included in EBIT	21.6	0.3	21.8	0.2	10.2
Adjusted EBIT	4.4	6.6	11.3	16.8	19.7

Alternative performance measures calculated on a constant currency basis	2023	2022	2023	2022	2022
EUR million	7-9	7-9	1-9	1-9	1-12
Invoicing	861.7	870.6	2,624.4	2,661.2	3,568.0
Translation difference	58.9	23.4	151.2	64.5	110.7
Invoicing calculated on a constant currency basis	920.6	894.0	2,775.6	2,725.7	3,678.7
Net sales	352.6	373.9	1,090.9	1,141.3	1,515.5
Translation difference	23.9	10.2	62.5	28.1	47.5
Net sales calculated on a constant currency basis	376.5	384.1	1,153.4	1,169.3	1,563.0
Adjusted EBIT	4.4	6.6	11.3	16.8	19.7
Translation difference	0.2	0.1	0.6	0.4	0.4
Adjusted EBIT calculated on a constant currency basis	4.7	6.8	11.9	17.2	20.2

Calculation of alternative performance measures

Alternative performance measure	Definitions
Invoicing	= Net sales + acquisition cost of consignment stock + cash discounts + exchange rate differences on sales
EBIT	= Net sales less material purchases and exchange rate differences on sales and purchases, less employee benefit expenses and other operating expenses, less depreciation, amortisation and impairment plus other operating income.
Adjusted EBIT	= EBIT excluding adjusting items
Adjusting items	= Adjusting items include gains or losses from the sale or discontinuation of business operations or assets, gains or losses from restructuring business operations, and impairment losses of goodwill and other non-current assets, or other income or expenses arising from rare events, and changes in estimates regarding the realisation of contingent consideration arising from business acquisitions.
Invoicing calculated on a constant currency basis	= Invoicing calculated with the average exchange rate of the corresponding period of the comparative year.
Net sales calculated on a constant currency basis	= Net sales calculated with the average exchange rate of the corresponding period of the comparative year.
Adjusted EBIT calculated on a constant currency basis	= Adjusted EBIT calculated with the average exchange rate of the corresponding period of the comparative year.
Net interest-bearing debt	= Interest-bearing liabilities - cash and cash equivalents
Investments	= Capitalised investments in property, plant and equipment and in intangible assets including goodwill arising from business combinations, as well as investments in associates and joint ventures and in other shares and holdings
Return on capital employed (ROCE), %	= $\frac{\text{EBIT}}{\text{Total assets - Non-interest-bearing liabilities (average between the beginning and the end of the year)}} \times 100$
Return on equity (ROE), %	= $\frac{\text{Profit for the period}}{\text{Equity total (average between the beginning and the end of the year)}} \times 100$
Gearing, %	= $\frac{\text{Net interest-bearing debt}}{\text{Equity total}} \times 100$
Equity ratio, %	= $\frac{\text{Equity total}}{\text{Total assets – Advances received}} \times 100$

Adjusting items

Adjusted EBIT excludes gains or losses from the sale or discontinuation of business operations or assets, gains or losses from restructuring business operations, and impairment losses of goodwill and other non-current assets, or other income or expenses arising from rare events, and changes in estimates regarding the realisation of contingent consideration arising from business acquisitions.

Adjusting items included in EBIT EUR million	2023 7-9	2022 7-9	2023 1-9	2022 1-9	2022 1-12
Restructuring costs	-	-0.3	-0.2	-0.3	-0.5
Impairments and write-downs	-21.6	-	-21.6	-	-9.8
Other	-	-	-	0.1	0.1
Adjusting items from continuing operations	-21.6	-0.3	-21.8	-0.2	-10.2

Adjusting items in the third quarter include an impairment loss on goodwill totalling EUR 21.4 million in the dose dispensing cash generating unit and a write-down of assets of EUR 0.2 million at Brunna warehouse, which was closed. Restructuring costs in 2023 relate to expert services. Adjusting items in 2022 relate to impairment of other tangible and intangible assets not yet available for use, the combination with Apoteksgruppen, the divestment of the staffing services business and restructuring costs related to the operating model.

Events after the period

Oriola to sell Svensk dos AB to Apotekstjänst Sverige AB

Oriola announced on 13 October 2023 that it had signed an agreement to sell all shares in Svensk dos AB to Apotekstjänst Sverige AB, and is thereby exiting the dose dispensing business in Sweden.

The agreed sales price in cash is SEK 110 million (approximately EUR 9.5 million). The transaction is subject to the approval of the Swedish Competition Authority (Konkurrensverket) and is expected to be completed no later than in the first quarter of 2024.

Svensk dos will be classified as held-for-sale in Oriola's consolidated financial statements starting from October 2023. More information in the [stock exchange release](#) on Oriola's website.